This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Nycomed
Nycomed was a Swiss pharmaceutical company that had been acquired by a major European private equity firm and had expanded significantly through inorganic growth. The E3 Life team joined the Commercial Operations team in 2011 to pursue growth opportunities in emerging markets.
Nycomed expanded its commercial footprint in Emerging Markets through numerous targeted licensing deals and a transformative acquisition in China, which established the foundation for further organic growth.
The expanded footprint supported by the E3 Life team was a key driver for Nycomed’s acquisition by a major strategic acquirer for an attractive investment return.